These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8679707)

  • 1. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA.
    Farid RS; Bianchi ME; Falciola L; Engelsberg BN; Billings PC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):532-9. PubMed ID: 8975778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin.
    Cryer JE; Johnson SW; Engelsberg BN; Billings PC
    Cancer Chemother Pharmacol; 1996; 38(2):163-8. PubMed ID: 8616907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
    Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
    Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
    J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
    Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
    Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B.
    Jamieson ER; Jacobson MP; Barnes CM; Chow CS; Lippard SJ
    J Biol Chem; 1999 Apr; 274(18):12346-54. PubMed ID: 10212205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM; Whitehead JP; Lippard SJ
    Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition and repair of DNA-cisplatin adducts.
    Woźniak K; Błasiak J
    Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
    Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells.
    Huang R; Wu T; Xu L; Liu A; Ji Y; Hu G
    FASEB J; 2002 Mar; 16(3):293-301. PubMed ID: 11874979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity.
    Pasheva EA; Ugrinova I; Spassovska NC; Pashev IG
    Int J Biochem Cell Biol; 2002 Jan; 34(1):87-92. PubMed ID: 11733188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of cisplatin adducts by cellular proteins.
    Kartalou M; Essigmann JM
    Mutat Res; 2001 Jul; 478(1-2):1-21. PubMed ID: 11406166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
    De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
    Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin inhibits synthesis of ribosomal RNA in vivo.
    Jordan P; Carmo-Fonseca M
    Nucleic Acids Res; 1998 Jun; 26(12):2831-6. PubMed ID: 9611224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.